These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18629778)

  • 101. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
    Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
    Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
    Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
    J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.
    Hao TB; Shi W; Shen XJ; Qi J; Wu XH; Wu Y; Tang YY; Ju SQ
    Br J Cancer; 2014 Oct; 111(8):1482-9. PubMed ID: 25157833
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Plasma DNA as cell death marker in elderly patients.
    Fournié GJ; Martres F; Pourrat JP; Alary C; Rumeau M
    Gerontology; 1993; 39(4):215-21. PubMed ID: 8244049
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Diagnostic value of circulating cell-free mtDNA in patients with suspected thyroid cancer: ND4/ND1 ratio as a new potential plasma marker.
    Jiang Z; Bahr T; Zhou C; Jin T; Chen H; Song S; Ikeno Y; Tian H; Bai Y
    Mitochondrion; 2020 Nov; 55():145-153. PubMed ID: 33035689
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.
    Cree IA; Uttley L; Buckley Woods H; Kikuchi H; Reiman A; Harnan S; Whiteman BL; Philips ST; Messenger M; Cox A; Teare D; Sheils O; Shaw J;
    BMC Cancer; 2017 Oct; 17(1):697. PubMed ID: 29061138
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
    Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
    Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing.
    Wielscher M; Pulverer W; Peham J; Hofner M; Rappaport CF; Singer C; Jungbauer C; Nöhammer C; Weinhäusel A
    BMC Clin Pathol; 2011 Sep; 11():11. PubMed ID: 21896199
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
    Kohler C; Radpour R; Barekati Z; Asadollahi R; Bitzer J; Wight E; Bürki N; Diesch C; Holzgreve W; Zhong XY
    Mol Cancer; 2009 Nov; 8():105. PubMed ID: 19922604
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Advances in the DNA Nanotechnology for the Cancer Biomarkers Analysis: Attributes and Applications.
    Xia LY; Tang YN; Zhang J; Dong TY; Zhou RX
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1105-1119. PubMed ID: 34979273
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors.
    Seefeld M; El Tarhouny S; Fan AX; Hahn S; Holzgreve W; Zhong XY
    Int J Biol Markers; 2008; 23(2):69-73. PubMed ID: 18629778
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Levels of circulating cell-free serum DNA in benign and malignant breast lesions.
    Zanetti-Dällenbach RA; Schmid S; Wight E; Holzgreve W; Ladewing A; Hahn S; Zhong XY
    Int J Biol Markers; 2007; 22(2):95-9. PubMed ID: 17549664
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
    El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
    Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease.
    Zanetti-Dällenbach R; Wight E; Fan AX; Lapaire O; Hahn S; Holzgreve W; Zhong XY
    Anticancer Res; 2008; 28(2A):921-5. PubMed ID: 18507037
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.
    Roth C; Pantel K; Müller V; Rack B; Kasimir-Bauer S; Janni W; Schwarzenbach H
    BMC Cancer; 2011 Jan; 11():4. PubMed ID: 21211028
    [TBL] [Abstract][Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.